Trial Profile
A Retrospective Study Investigating Safety of Nintedanib in Idiopathic Pulmonary Fibrosis Patients Treated with Nintedanib within a Compassionate Use Program (CUP) in Latin America
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 10 Jul 2018
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Expanded access
- 10 Jul 2018 New trial record
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society.